References:
1. Negrin RS. Introduction to the review series on “Advances in hematopoietic cell transplantation”. Am Soc Hematology; 2014.
2. Harris AC, Ferrara JL, Levine JE. Advances in predicting acute GVHD. British journal of haematology. 2013;160(3):288-302.
3. Qian L, Wu Z, Shen J. Advances in the treatment of acute graft‐versus‐host disease. Journal of cellular and molecular medicine. 2013;17(8):966-75.
4. Zhao K, Lou R, Huang F, Peng Y, Jiang Z, Huang K, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2015;21(1):97-104.
5. Wolf D, von Lilienfeld-Toal M, Wolf AM, Schleuning M, von Bergwelt-Baildon M, Held SA, et al. Novel treatment concepts for graft-versus-host disease. Blood, The Journal of the American Society of Hematology. 2012;119(1):16-25.
6. Lim J-Y, Park M-J, Im K-I, Kim N, Jeon E-J, Kim E-J, et al. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model. Cell transplantation. 2014;23(6):703-14.
7. Bernardo M, Ball L, Cometa A, Roelofs H, Zecca M, Avanzini M, et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone marrow transplantation. 2011;46(2):200.
8. Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T regulatory cells. Experimental hematology. 2008;36(3):309-18.
9. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 2009;30(5):656-65.
10. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815-22.
11. Ghannam S, Pène J, Moquet-Torcy G, Jorgensen C, Yssel H. Correction: mesenchymal stem cells inhibit human th17 cell differentiation and function and induce a T regulatory cell phenotype. The Journal of Immunology. 2013;191(11):5777-.
12. Stenger EO, Krishnamurti L, Galipeau J. Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation. BMC immunology. 2015;16(1):74.
13. Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). American journal of blood research. 2013;3(3):225.
14. Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biology of blood and marrow transplantation. 2014;20(3):375-81.
15. Berger M, Signorino E, Muraro M, Quarello P, Biasin E, Nesi F, et al. Monitoring of TNFR1, IL-2Rα, HGF, CCL8, IL-8 and IL-12p70 following HSCT and their role as GVHD biomarkers in paediatric patients. Bone marrow transplantation. 2013;48(9):1230.
16. Perkins JD, Nelson DL, Rakela J, Grambsch PM, Krom R. Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation. 1989;47(1):77-81.
17. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702-8.
18. Lee SH, Lee M, Yoo K, Kim D, Son M, Sung K, et al. Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation. Bone marrow transplantation. 2013;48(8):1040-5.
19. Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S, et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood. 2008;112(4):1539-42.
20. August K, Chiang K, Bostick R, Flanders W, Waller E, Langston A, et al. Biomarkers of immune activation to screen for severe, acute GVHD. Bone marrow transplantation. 2011;46(4):601.
21. Marafini I, Di Sabatino A, Zorzi F, Monteleone I, Sedda S, Cupi M, et al. Serum regenerating islet‐derived 3‐alpha is a biomarker of mucosal enteropathies. Alimentary pharmacology & therapeutics. 2014;40(8):974-81.
22. Ito S, Barrett AJ. ST2: the biomarker at the heart of GVHD severity. Blood. 2015;125(1):10-1.
23. Kanaya M, Shibuya K, Hirochika R, Kanemoto M, Ohashi K, Okada M, et al. Soluble DNAM-1, as a predictive biomarker for acute graft-versus-host disease. PloS one. 2016;11(6):e0154173.
24. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biology of blood and marrow transplantation. 2010;16(6):838-47.
25. Kallekleiv M, Larun L, Bruserud Ø, Hatfield KJ. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Cytotherapy. 2016;18(2):172-85.
26. Bacigalupo A. Mesenchymal stem cells and haematopoietic stem cell transplantation. Best Practice & Research Clinical Haematology. 2004;17(3):387-99.
27. Tian Y, Deng Y, Huang Y, Wang Y. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Immunological investigations. 2008;37(1):29-42.
28. Liu K, Chen Y, Zeng Y, Xu L, Liu D, Chen H, et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study. Stem cells and development. 2011;20(10):1679-85.
29. Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. Journal of Clinical Oncology. 2000;18(2):307-.
30. Angelopoulou M, Novelli E, Grove JE, Rinder HM, Civin C, Cheng L, et al. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Experimental hematology. 2003;31(5):413-20.
31. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental hematology. 2002;30(1):42-8.
32. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101(9):3722-9.
33. William TT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75(3):389-97.
34. Frassoni F. Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hemopoietic stem cell transplants, reduce acute and chronic graft-versus-host disease: a matched pair analysis. Bone Marrow Transplant. 2002;29:S2.
35. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet. 2004;363(9419):1439-41.
36. Zhao K, Liu Q. The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. Journal of hematology & oncology. 2016;9(1):46.
37. Nasef A. Role of Bone Marrow Derived Mesenchymal Stem Cells in Management of Graft Versus Host Disease. Stem Cell Biology in Normal Life and Diseases: IntechOpen; 2013.
38. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biology of blood and marrow transplantation. 2005;11(5):389-98.
39. Ringdén O, Labopin M, Gorin N-C, Le Blanc K, Rocha V, Gluckman E, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of clinical oncology. 2004;22(3):416-23.
40. Wu K-H, Tsai C, Wu H-P, Sieber M, Peng C-T, Chao Y-H. Human application of ex vivo expanded umbilical cord-derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell transplantation. 2013;22(11):2041-51.
41. Chao Y, Tsai C, Peng C, Wu H, Chan C, Weng T, et al. Cotransplantation of umbilical cord MSCs to enhance engraftment of hematopoietic stem cells in patients with severe aplastic anemia. Bone marrow transplantation. 2011;46(10):1391-2.
42. Macmillan M, Blazar B, DeFor T, Wagner J. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I–II clinical trial. Bone marrow transplantation. 2009;43(6):447.
43. Kimura T, Asada R, Wang J, Kimura T, Morioka M, Matsui K, et al. Identification of Long‐Term Repopulating Potential of Human Cord Blood‐Derived CD34− flt3− Severe Combined Immunodeficiency‐Repopulating Cells by Intra‐Bone Marrow Injection. Stem Cells. 2007;25(6):1348-55.
44. Pereira R, Halford K, O’hara M, Leeper D, Sokolov B, Pollard M, et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proceedings of the national academy of sciences. 1995;92(11):4857-61.
45. Bensidhoum M, Chapel A, Francois S, Demarquay C, Mazurier C, Fouillard L, et al. Homing of in vitro expanded Stro-1-or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood. 2004;103(9):3313-9.
46. Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Experimental hematology. 2001;29(2):244-55.
47. Horwitz E, Dominici M. How do mesenchymal stromal cells exert their therapeutic benefit? Cytotherapy. 2008;10(8):771-4.
48. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem cells. 2006;24(4):1030-41.
49. Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. Phenotypic and functional comparison of cultures of marrow‐derived mesenchymal stem cells (MSCs) and stromal cells. Journal of cellular physiology. 1998;176(1):57-66.
50. Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. The Journal of clinical investigation. 2000;106(11):1331-9.
51. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007;21(8):1733.
52. Wang L, Zhang H, Guan L, Zhao S, Gu Z, Wei H, et al. Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models. Oncotarget. 2016;7(38):61764.
53. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003;102(10):3837-44.
54. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, et al. Cotransplantation of ex vivo–expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood. 2007;110(7):2764-7.
55. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. Journal of hematotherapy & stem cell research. 2000;9(6):841-8.
56. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nature medicine. 2003;9(10):1269.
57. Olerup O, Zetterquist H. HLA‐DR typing by PCR amplification with sequence‐specific primers (PCR‐SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor‐recipient matching in cadaveric transplantation. Tissue antigens. 1992;39(5):225-35.
58. Copelan E, Biggs J, Szer J, Thompson J, Crilley P, Brodsky I, et al., editors. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). Seminars in oncology; 1993.
59. Socié G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98(13):3569-74.
60. Clift R, Buckner C, Thomas E, Bensinger W, Bowden R, Bryant E, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84(6):2036-43.
61. Storb R, Deeg HJ, Fisher L, Appelbaum F, Buckner CD, Bensinger W, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood. 1988;71(2):293-8.
62. Przepiorka D, Weisdorf D, Martin P, Klingemann H, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone marrow transplantation. 1995;15(6):825-8.
63. Atkinson K, Horowitz M, Gale R, Lee M, Rimm A, Bortin M. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone marrow transplantation. 1989;4(3):247-54.
64. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838-43.
65. Troeger A, Meisel R, Moritz T, Dilloo D. Immunotherapy in allogeneic hematopoietic stem cell transplantation–not just a case for effector cells. Bone marrow transplantation. 2005;35(S1):S59.
66. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia. 2007;21(2):304-10.
67. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia. 2008;22(3):593.
68. Levine JE, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ferrara JL, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012;119(16):3854-60.
69. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. New England Journal of Medicine. 2013;369(6):529-39.
70. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4(6):573-81.
71. Nabekura T, Kanaya M, Shibuya A, Fu G, Gascoigne NR, Lanier LL. Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. Immunity. 2014;40(2):225-34.
72. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. Journal of Experimental Medicine. 2003;198(4):557-67.
73. Tahara-Hanaoka S, Shibuya K, Kai H, Miyamoto A, Morikawa Y, Ohkochi N, et al. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood. 2006;107(4):1491-6.
74. Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI insight. 2017;2(3).
75. Huang X, Liu D, Liu K, Xu L, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone marrow transplantation. 2006;38(4):291.